Literature DB >> 24490050

Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review.

Omar Al Ustwani1, James Lohr1, Grace Dy1, Charles Levea2, Gregory Connolly3, Pradeep Arora1, Renuka Iyer1.   

Abstract

Entities:  

Year:  2014        PMID： 24490050      PMCID： PMC3904030          DOI： 10.3978/j.issn.2078-6891.2013.042

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  15 in total

1.  A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.

Authors:  M C Fung; A M Storniolo; B Nguyen; M Arning; W Brookfield; J Vigil
Journal:  Cancer       Date:  1999-05-01       Impact factor: 6.860

2.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

3.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

4.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

5.  Gemcitabine-induced hemolytic uremic syndrome: a case report.

Authors:  T Brodowicz; S Breiteneder; C Wiltschke; C C Zielinski
Journal:  J Natl Cancer Inst       Date:  1997-12-17       Impact factor: 13.506

6.  Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Authors:  E S Casper; M R Green; D P Kelsen; R T Heelan; T D Brown; C D Flombaum; B Trochanowski; P G Tarassoff
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

7.  Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.

Authors:  C Mark Taylor; Sam Machin; Stephen J Wigmore; Tim H J Goodship
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

8.  Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.

Authors:  I Glezerman; M G Kris; V Miller; S Seshan; C D Flombaum
Journal:  Clin Nephrol       Date:  2009-02       Impact factor: 0.975

Review 9.  Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?

Authors:  Ethan McCaleb Gore; Benjamin Scott Jones; Marisa B Marques
Journal:  J Clin Apher       Date:  2009       Impact factor: 2.821

10.  Atypical relapse of hemolytic uremic syndrome after transplantation.

Authors:  Karolien H Olie; Sandrine Florquin; Jaap W Groothoff; René Verlaak; Lisa Strain; Timothy H J Goodship; Jan J Weening; Jean-Claude Davin
Journal:  Pediatr Nephrol       Date:  2004-08-05       Impact factor: 3.714
View more
  18 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

Review 2.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.

Authors:  Christopher D Hamad; Zachary C Hoelscher; Amanda Tchakarov; Jaya Kala
Journal:  CEN Case Rep       Date:  2022-01-07

4.  Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.

Authors:  Maximilien Grall; Florence Daviet; Noémie Jourde Chiche; François Provot; Claire Presne; Jean-Philippe Coindre; Claire Pouteil-Noble; Alexandre Karras; Dominique Guerrot; Arnaud François; Ygal Benhamou; Agnès Veyradier; Véronique Frémeaux-Bacchi; Paul Coppo; Steven Grangé
Journal:  BMC Nephrol       Date:  2021-07-21       Impact factor: 2.388

Review 5.  Systematic review of atypical hemolytic uremic syndrome biomarkers.

Authors:  Rupesh Raina; Sidharth K Sethi; Marie-Agnès Dragon-Durey; Amrit Khooblall; Divya Sharma; Priyanka Khandelwal; Ron Shapiro; Olivia Boyer; Hui Kim Yap; Arvind Bagga; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2022-02-03       Impact factor: 3.651

Review 6.  Nephrotoxicity of recent anti-cancer agents.

Authors:  Norbert Lameire
Journal:  Clin Kidney J       Date:  2013-11-26

Review 7.  Cancer-associated thrombotic microangiopathy.

Authors:  K Govind Babu; Gita R Bhat
Journal:  Ecancermedicalscience       Date:  2016-06-28

8.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

9.  Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab.

Authors:  Marco Allinovi; Calogero Lino Cirami; Leonardo Caroti; Giulia Antognoli; Silvia Farsetti; Maria Pia Amato; Enrico Eugenio Minetti
Journal:  Clin Kidney J       Date:  2017-02-16

10.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.